8-K: BioMarin Reports Q1 2026 Results, Raises Full-Year Guidance

BioMarin Pharmaceutical Inc. announced first quarter 2026 financial results, reporting $766 million in total revenues and increasing its full-year revenue guidance to $3.825 billion - $3.925 billion.

Summary

• BioMarin Pharmaceutical Inc. reported first quarter 2026 total revenues of $766 million, a 3% increase year-over-year.
• The company raised its full-year 2026 total revenues guidance to a range of $3.825 billion to $3.925 billion, representing an accelerated growth rate of 20% year-over-year at the midpoint.
• This updated guidance reflects the addition of GALAFOLD and POMBILITI + OPFOLDA to BioMarin's commercial portfolio following the acquisition of Amicus Therapeutics.
• GAAP Net Income for the quarter decreased to $106 million from $186 million in the prior year, attributed to higher operating expenses.
• Non-GAAP Income decreased to $149 million from $221 million in the prior year, also due to increased expenses.
• The company secured approximately $3.7 billion in non-convertible debt financing to support the Amicus acquisition.
• BioMarin generated $221 million in operating cash flows in the first quarter and ended the period with approximately $2 billion in total cash.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, primarily driven by the significant increase in full-year revenue guidance and the strategic acquisition, despite a dip in quarterly net income due to integration costs.

Positives

• Total revenues increased 3% year-over-year to $766 million in Q1 2026.
• Full-year 2026 total revenues guidance was raised to $3.825 billion - $3.925 billion, indicating an accelerated growth rate of 20% year-over-year at the midpoint.
• The acquisition of Amicus Therapeutics and the addition of GALAFOLD and POMBILITI + OPFOLDA are expected to strengthen and accelerate near-to-mid-term growth.
• Enzyme Therapies revenue grew 6% year-over-year in Q1 2026.
• VOXZOGO revenue saw a 3% year-over-year increase in Q1 2026, with the number of treated children increasing by over 20% year-over-year.
• PALYNZIQ revenue is expected to increase over time due to continued patient demand and label expansion for younger age groups.
• Secured $3.7 billion in non-convertible debt financing at favorable pricing for the Amicus acquisition.
• Generated $221 million in operating cash flows in Q1 2026, with total cash of approximately $2 billion at quarter-end.

Negatives

• GAAP Net Income decreased by 43% to $106 million in Q1 2026 compared to $186 million in Q1 2025.
• Non-GAAP Income decreased by 33% to $149 million in Q1 2026 compared to $221 million in Q1 2025.
• GAAP Diluted EPS decreased by 43% to $0.54 in Q1 2026 from $0.95 in Q1 2025.
• Non-GAAP Diluted EPS decreased by 33% to $0.76 in Q1 2026 from $1.13 in Q1 2025.
• Cost of sales increased, including a $31 million charge for an unsuccessful NAGLAZYME manufacturing process qualification campaign.
• Selling, General & Administrative (SG&A) expenses increased due to incremental administrative costs for corporate initiatives and pre-close Amicus acquisition costs.
• Research and Development spend increased to support the BMN 401 program.
• ROCTAVIAN revenue decreased by 73% due to its voluntary withdrawal from the market.

Risks

• The acquisition of Amicus Therapeutics is expected to be slightly dilutive to full-year 2026 Non-GAAP Diluted EPS.
• Intangible amortization from the Amicus acquisition will impact GAAP results over future periods.
• The company faces regulatory uncertainty and potential impacts from macroeconomic and external factors, geopolitical instability, wars, and military conflicts.
• The success of current and planned preclinical studies and clinical trials, and the timing of data releases, are subject to risk.
• BioMarin's ability to successfully manufacture its commercial products and product candidates is a risk.
• Decisions by regulatory authorities concerning products and product candidates carry inherent risks.
• The market for each product and BioMarin's ability to meet product demand are subject to risk.
• Factors detailed in BioMarin's SEC filings, including the Risk Factors section of its Annual Report on Form 10-K for the year ended December 31, 2025, could impact future results.

Future Outlook

The company has raised its full-year 2026 total revenues guidance to between $3.825 billion and $3.925 billion, reflecting an accelerated growth rate of 20% year-over-year at the midpoint. This outlook incorporates the recent acquisition of Amicus Therapeutics and the addition of GALAFOLD and POMBILITI + OPFOLDA. Approximately two-thirds of the 2026 Non-GAAP Diluted EPS is expected in the second half of the year, with Q2 Non-GAAP Diluted EPS projected to be modestly higher than Q1.

Management Comments

• "With the acquisition of Amicus Therapeutics complete, the addition of GALAFOLD and POMBILITI + OPFOLDA to our commercial portfolio allows us to reach patients with Fabry and Pompe diseases and meaningfully strengthens and accelerates our near-to-mid-term growth rates," said Alexander Hardy, President and Chief Executive Officer.
• "We expect these high-growth assets to support our strongest financial performance yet in 2026."
• "Next quarter, we look forward to updating you on the longerterm outlook of the Amicus integration based on our plans to leverage our global scale to expand the potential of these transformative therapies."
• "With a faster-growing commercial portfolio, together with two near-term Phase 3 data readouts and ongoing pipeline progress expected over the coming quarters, we are well-positioned to drive innovation, create shareholder value, and improve outcomes for patients worldwide."

Industry Context

StockSavvy.ai notes that BioMarin's increased revenue guidance and strategic acquisition of Amicus Therapeutics align with a broader trend in the rare disease biotechnology sector towards consolidation and portfolio expansion to drive sustainable growth and market leadership. The integration of new, high-growth assets is a common strategy to offset patent cliffs and enhance long-term value.

Comparison to Industry Standards

• The reported 3% year-over-year revenue growth for Q1 2026 is modest, but the significant increase in full-year guidance to 20% growth suggests strong performance expected from newly acquired assets.
• The $31 million charge for an unsuccessful manufacturing campaign is a notable operational setback, but the company's ability to absorb this and still raise guidance indicates resilience.
• The company's focus on rare genetic diseases places it in a specialized segment of the pharmaceutical industry, where product launches and acquisitions can have a substantial impact on growth rates, often exceeding broader pharmaceutical industry averages.
• The financing of the Amicus acquisition through $3.7 billion in non-convertible debt is a significant capital markets event, reflecting investor confidence in the company's growth prospects, though it increases leverage.

Stakeholder Impact

• Shareholders are likely to view the increased full-year revenue guidance positively, indicating potential for future value creation.
• Patients with rare diseases (Fabry, Pompe, PKU, achondroplasia, ENPP1 deficiency) stand to benefit from the expanded portfolio and ongoing pipeline development, including new approvals and data readouts.
• Employees may experience impacts related to the integration of Amicus Therapeutics, potentially involving organizational adjustments.
• Creditors and debt holders are impacted by the $3.7 billion debt financing, which increases the company's leverage but is intended to support growth.

Next Steps

• Update on the longer-term outlook of the Amicus integration in the next quarter.
• Share BMN 401 Phase 3 topline data in children ages 1-to-12 year-old with ENPP1 deficiency in the second quarter.
• Share Phase 3 topline data for VOXZOGO for hypochondroplasia in the second quarter.
• Expect notification of sNDA acceptance for VOXZOGO full approval by Q3 2026.
• Anticipate regulatory submissions for BMN 401 and VOXZOGO (hypochondroplasia) in 2H26 if data is supportive.
• Potential first-in-disease launch of BMN 401 in 2027.
• Potential first-in-class launch of VOXZOGO for hypochondroplasia in 2027.
• Data update from the 12 mg/kg dose cohort of BMN 351 expected by year-end 2026.

Key Dates

Recommendation

The significant increase in full-year revenue guidance, driven by the strategic acquisition of Amicus Therapeutics and the integration of high-growth assets, coupled with a robust pipeline and positive outlook for key products like VOXZOGO, presents a compelling growth story. Despite short-term impacts on net income due to acquisition costs, the long-term strategic positioning and accelerated growth trajectory warrant a strong buy recommendation.

Keywords

BioMarin Pharmaceutical, SEC Filing, 8-K, Financial Results, Q1 2026, Revenue Guidance, Rare Disease, Biotechnology